Table 3 Assessment of CGRPmAbs' suitability and efficacy
Item | Answer | frequency, % (n = 312) |
|---|---|---|
The MMD threshold for recommending CGRPmAbs | ≥ 4 | 71, 22.8% |
≥ 6 | 68, 21.8% | |
≥ 8 | 76, 24.4% | |
≥ 10 | 81, 26.0% | |
≥ 12 | 4, 1.3% | |
≥ 15 | 12, 3.8% | |
The number of migraine preventives you usually try before prescribing a CGRPmAb | 1 | 64, 20.5% |
2 | 170, 54.5% | |
3 | 62, 19.9% | |
4 | 11, 3.5% | |
≥ 5 | 5, 1.6% | |
When to assess the response to a CGRPmAb in patients with EM | After 1 month | 46, 14.7% |
After 2 months | 30, 9.6% | |
After 3 months | 217, 69.6% | |
After 4–6 months | 19, 6.1% | |
After 7–9 months | 0, 0% | |
After 10–12 months | 0, 0% | |
When to assess the response to a CGRPmAb in patients with CM | After 1 month | 34, 10.9% |
After 2 months | 30, 9.6% | |
After 3 months | 188, 60.3% | |
After 4–6 months | 55, 17.6% | |
After 7–9 months | 5, 1.6% | |
After 10–12 months | 0, 0% | |
The percentage of EM patients whose MMDs have decreased ≥ 50% | < 20% | 7, 2.2% |
≥ 20% and < 40% | 11, 3.5% | |
≥ 40% and < 60% | 85, 27.2% | |
≥ 60% and < 80% | 102, 32.7% | |
≥ 80% | 107, 34.3% | |
The percentage of CM patients whose MMDs have decreased ≥ 50% | < 20% | 16, 5.1% |
≥ 20% and < 40% | 53, 17.0% | |
≥ 40% and < 60% | 104, 33.3% | |
≥ 60% and < 80% | 66, 21.2% | |
≥ 80% | 73, 23.4% | |
The most frequently reported reason for responders to discontinue CGRPmAbs | Cost | 76, 24.4% |
Adverse effects, safety (including injection site reaction, constipation, pregnancy) | 39, 12.5% | |
Frequency of hospital visits | 6, 1.9% | |
Enough improvement of migraine | 169, 54.2% |